Get the Daily Brief
Latest Biotech News
CRISPR-Edited Mosquitoes Halt Malaria Transmission with Single Amino Acid Change
Researchers used CRISPR-Cas9 gene editing to introduce a naturally occurring variant into the mosquito FREP1 gene, rendering mosquitoes resistant to malaria parasite transmission. This single...
New AI System Predicts Muscle Stem Cell Differentiation from Imaging
Researchers developed a nondestructive imaging and machine learning platform that forecasts the efficiency of induced pluripotent stem cells differentiating into muscle stem cells. Using...
AstraZeneca's Gefurulimab Achieves Phase 3 Success in Autoimmune Myasthenia Gravis
AstraZeneca announced positive Phase 3 PREVAIL trial results for gefurulimab, a self-administered C5 complement inhibitor targeting generalized myasthenia gravis (gMG). Gefurulimab met primary and...
AI and Bioinformatics Firms TileDB and Databricks Partner to Integrate Life Sciences Data Platforms
TileDB and Databricks have entered an agreement to integrate their respective data management platforms for healthcare and life sciences. This collaboration will enable data from TileDB’s...
Dispatch Bio Launches with $216M to Target Solid Tumors
Dispatch Bio emerged with $216 million in funding, unveiling a novel immunotherapy platform designed to treat diverse and hard-to-target solid tumors. Founded in 2022 through collaborations...
FDA Delays and Challenges in Gene and Cancer Therapy Approvals
Recent regulatory setbacks have impacted several biotech therapies. The FDA extended the review for GSK’s multiple myeloma drug Blenrep as the company prepares a relaunch after its previous...
Abivax Ulcerative Colitis Drug Scores Strong Phase 3 Results
Abivax’s investigational oral miRNA-enhancer drug obefazimod demonstrated compelling clinical remission in two Phase 3 trials involving moderately to severely active ulcerative colitis patients...
Sanofi Acquires Vicebio to Expand Respiratory Vaccine Portfolio
Sanofi announced a $1.15 billion upfront acquisition of London-based biotech Vicebio, enhancing its position in respiratory virus vaccines. Vicebio’s Molecular Clamp technology stabilizes viral...
Thermo Fisher Scientific Raises 2025 Guidance Following Robust Q2
Thermo Fisher Scientific reported a 3 percent year-over-year revenue growth to $10.86 billion in Q2, beating analyst expectations. The company raised its full-year revenue guidance to between...
Long-Read Sequencing Sheds Light on Human Genome Structural Variation
Two independent international research groups applied long-read DNA sequencing to samples from the 1000 Genomes Project, unveiling an unprecedented view of structural genetic variation across...
Gut Microbial Protein Rapidly Signals Appetite Suppression to Brain
Research from Duke University elucidated a gut-brain communication path enabling real-time appetite regulation through detection of a microbial protein. Specialized colonic neuropod cells sense...
Advances in Machine Learning and Automation for Biotech Discovery and Manufacturing
Recent technological innovations harnessing machine learning and automation are transforming biotech research and production. Techniques such as Bayesian optimization integrated with...
Autoantibodies Influence Cancer Immunotherapy Response
A study from Yale School of Medicine and Fred Hutchinson Cancer Center reveals that naturally occurring autoantibodies can significantly influence patient response to checkpoint immunotherapy in...
Gene Edit Stops Malaria Transmission in Mosquitoes
Researchers from UCSD and Johns Hopkins developed a CRISPR-Cas9 gene edit that introduces a naturally occurring amino acid variant into the FREP1 gene of Anopheles mosquitoes, rendering them...
FDA and Drug Development: Elevidys and Replimune Setbacks
Recent developments highlight regulatory challenges facing cutting-edge therapies. The FDA has extended its review of GSK's multiple myeloma drug Blenrep, delaying its relaunch efforts. Sarepta...
Abivax Phase 3 Data Sparks Market Surge and New Ulcerative Colitis Treatment Hopes
Abivax announced highly positive Phase 3 results for its orally available miRNA therapy obefazimod targeting moderately to severely active ulcerative colitis (UC). The pooled remission rate...
Dispatch Bio Launches with $216M to Target Solid Tumors via Novel Immunotherapy
Dispatch Bio, a new biotechnology startup specializing in immunotherapy, has emerged with $216 million in funding to develop a universal approach to treating solid tumors. The company’s Flare...
Thermo Fisher and CDMOs Report Strong Earnings Amid Market Challenges
Thermo Fisher Scientific delivered robust Q2 financial results, beating revenue and earnings expectations, prompting an 11% stock surge. Revised full-year guidance includes higher revenue and...
Genomic Advances Reveal Complex Human Variation and Epigenetic Mechanisms
Two recent studies leveraging long-read sequencing technologies provide unprecedented insights into structural variants and nearly complete human genomes from the 1000 Genomes Project. These...
Sanofi Acquires Vicebio to Expand Non-mRNA Respiratory Vaccine Portfolio
Sanofi announced a strategic acquisition of London-based biotech Vicebio for $1.15 billion upfront plus up to $450 million in milestones. Vicebio's lead candidate, VXB-241, a bivalent vaccine...